Handelsbanken Fonder AB Sells 34,965 Shares of Hologic, Inc. $HOLX

Handelsbanken Fonder AB decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 134,744 shares of the medical equipment provider’s stock after selling 34,965 shares during the quarter. Handelsbanken Fonder AB’s holdings in Hologic were worth $9,094,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of HOLX. Fifth Lane Capital LP bought a new stake in shares of Hologic during the third quarter worth $202,000. R Squared Ltd bought a new stake in Hologic during the 3rd quarter worth about $646,000. DNB Asset Management AS lifted its position in Hologic by 1.6% during the 3rd quarter. DNB Asset Management AS now owns 264,193 shares of the medical equipment provider’s stock valued at $17,830,000 after purchasing an additional 4,179 shares during the period. Choreo LLC lifted its position in Hologic by 9.6% during the 3rd quarter. Choreo LLC now owns 4,228 shares of the medical equipment provider’s stock valued at $285,000 after purchasing an additional 372 shares during the period. Finally, West Family Investments Inc. bought a new position in shares of Hologic in the 3rd quarter valued at about $229,000. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their target price for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Morgan Stanley upped their target price on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

HOLX stock opened at $75.36 on Monday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.49. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The firm has a market cap of $16.82 billion, a PE ratio of 31.40, a P/E/G ratio of 2.24 and a beta of 0.72. The business’s 50-day moving average price is $74.95 and its two-hundred day moving average price is $72.16.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company earned $0.87 earnings per share. The firm’s revenue was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.